{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:27:27Z","timestamp":1790958447474,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","award":["R37CA251877"],"award-info":[{"award-number":["R37CA251877"]}],"id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","award":["15-70-25-BRYA"],"award-info":[{"award-number":["15-70-25-BRYA"]}],"id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA179193"],"award-info":[{"award-number":["CA179193"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA42978"],"award-info":[{"award-number":["CA42978"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA175747"],"award-info":[{"award-number":["CA175747"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA199235"],"award-info":[{"award-number":["CA199235"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35GM122575"],"award-info":[{"award-number":["R35GM122575"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA201402"],"award-info":[{"award-number":["R01CA201402"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","award":["388222"],"award-info":[{"award-number":["388222"]}],"id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["NNCI-2025233"],"award-info":[{"award-number":["NNCI-2025233"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001784","name":"Pancreatic Cancer Action Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.canlet.2021.05.031","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:34:28Z","timestamp":1623108868000},"page":"66-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin"],"prefix":"10.1016","volume":"517","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5751-6345","authenticated-orcid":false,"given":"Wen-Hsuan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy-Tien Thi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4869-7110","authenticated-orcid":false,"given":"Chia-Hsin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4026-0942","authenticated-orcid":false,"given":"Kirsten L.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0172-7530","authenticated-orcid":false,"given":"Haoqiang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon W.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7751-2747","authenticated-orcid":false,"given":"Channing J.","family":"Der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Cerione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Antonyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.05.031_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: The critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.canlet.2021.05.031_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.05.031_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2021.05.031_bib4","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.05.031_bib5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","article-title":"Dragging Ras back in the ring","volume":"25","author":"Stephen","year":"2014","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2021.05.031_bib6","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2021.05.031_bib7","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2021.05.031_bib8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: Know the enemy","volume":"335","author":"Papke","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.05.031_bib9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.05.031_bib10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1126\/science.aad6204","article-title":"Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism","volume":"351","author":"Lito","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.05.031_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.05.031_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Canc. Discov."},{"key":"10.1016\/j.canlet.2021.05.031_bib13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-019-0368-8","article-title":"Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer","volume":"25","author":"Bryant","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2021.05.031_bib14","article-title":"Extracellular vesicles and their roles in cancer progression","volume":"143\u2013170","author":"Chang","year":"2021"},{"key":"10.1016\/j.canlet.2021.05.031_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cell.2019.02.029","article-title":"Reassessment of exosome composition","volume":"177","author":"Jeppesen","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.05.031_bib16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.devcel.2019.03.011","article-title":"Loss of sirtuin 1 alters the secretome of breast cancer cells by impairing lysosomal integrity","volume":"49","author":"Latifkar","year":"2019","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2021.05.031_bib17","first-page":"5315","article-title":"IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), bax, caspases, and anticancer drugs","volume":"58","author":"Tamm","year":"1998","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.05.031_bib18","first-page":"1","article-title":"A unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Canc. Cell Int."},{"key":"10.1016\/j.canlet.2021.05.031_bib19","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.223826","article-title":"Survivin at a glance","volume":"132","author":"Wheatley","year":"2019","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2021.05.031_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.surg.2004.05.023","article-title":"Survivin expression is a prognostic marker in pancreatic cancer patients","volume":"136","author":"Kami","year":"2004","journal-title":"Surgery"},{"key":"10.1016\/j.canlet.2021.05.031_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12957-015-0605-7","article-title":"Survivin expression and serum levels in pancreatic cancer","volume":"13","author":"Dong","year":"2015","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.canlet.2021.05.031_bib22","doi-asserted-by":"crossref","first-page":"19774","DOI":"10.1074\/jbc.M116.725705","article-title":"Microvesicle cargo and function changes upon induction of cellular transformation","volume":"291","author":"Kreger","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.05.031_bib23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.05.031_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8120111","article-title":"The enrichment of survivin in exosomes from breast cancer cells treated with paclitaxel promotes cell survival and chemoresistance","volume":"8","author":"Kreger","year":"2016","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2021.05.031_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1158\/1541-7786.MCR-06-0263","article-title":"Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines","volume":"5","author":"Hollestelle","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2021.05.031_bib26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mc.20607","article-title":"KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 Activation\u202f: implication for combinatorial approach","volume":"362","author":"Yoon","year":"2010","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.canlet.2021.05.031_bib27","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.05.031_bib28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bbcan.2014.01.003","article-title":"Survivin and YM155: how faithful is the liaison?","volume":"1845","author":"Rauch","year":"2014","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2021.05.031_bib29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41568-018-0048-x","article-title":"Nutrient scavenging in cancer","volume":"18","author":"Finicle","year":"2018","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2021.05.031_bib30","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.tcb.2017.06.003","article-title":"Metabolic interactions in the tumor microenvironment","volume":"27","author":"Lyssiotis","year":"2017","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2021.05.031_bib31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0360-3016(00)00803-8","article-title":"Pancreatic tumors show high levels of hypoxia","volume":"48","author":"Koong","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2021.05.031_bib32","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","article-title":"Hypoxia and cancer","volume":"85","author":"Brahimi-Horn","year":"2007","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.canlet.2021.05.031_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tibs.2013.12.004","article-title":"KRAS: Feeding pancreatic cancer proliferation","volume":"39","author":"Bryant","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.canlet.2021.05.031_bib34","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1042\/BST20170521","article-title":"RAS in pancreatic cancer","volume":"47","author":"Lanfredini","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.canlet.2021.05.031_bib35","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-019-0367-9","article-title":"Protective autophagy elicited by RAF\u2192MEK\u2192ERK inhibition suggests a treatment strategy for RAS-driven cancers","volume":"25","author":"Kinsey","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2021.05.031_bib36","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1158\/1078-0432.CCR-08-1946","article-title":"Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors","volume":"15","author":"Satoh","year":"2009","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.05.031_bib37","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1200\/JCO.2008.21.1862","article-title":"Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer","volume":"27","author":"Giaccone","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.05.031_bib38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10637-009-9333-6","article-title":"A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma","volume":"29","author":"Lewis","year":"2011","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2021.05.031_bib39","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/annonc\/mdr353","article-title":"A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer","volume":"23","author":"Tolcher","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2021.05.031_bib40","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1126\/science.1153124","article-title":"Ceramide triggers budding of exosome vesicles into multivesicular endosomes","volume":"319","author":"Trajkovic","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.05.031_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3958-1","article-title":"Mechanism of recipient cell-dependent differences in exosome uptake","volume":"18","author":"Horibe","year":"2018","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2021.05.031_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034045","article-title":"Tumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis","volume":"7","author":"Kawamoto","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2021.05.031_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-30446-1","article-title":"Exosomes released from pancreatic cancer cells enhance angiogenic activities via dynamin-dependent endocytosis in endothelial cells in vitro","volume":"8","author":"Chiba","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2021.05.031_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-72503-8","article-title":"Rab13 regulates sEV secretion in mutant KRAS colorectal cancer cells","volume":"10","author":"Hinger","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2021.05.031_bib45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature14581","article-title":"Glypican-1 identifies cancer exosomes and detects early pancreatic cancer","volume":"523","author":"Melo","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.05.031_bib46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/1078-0432.CCR-10-0248","article-title":"Serum biomarker panels for the detection of pancreatic cancer","volume":"17","author":"Brand","year":"2011","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.05.031_bib47","first-page":"340","article-title":"The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates","volume":"13","author":"Poruk","year":"2013","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.canlet.2021.05.031_bib48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/1097-0142(20010715)92:2<271::AID-CNCR1319>3.0.CO;2-0","article-title":"Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors","volume":"92","author":"Satoh","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2021.05.031_bib49","first-page":"1731","article-title":"An HLA-a24-restricted cytotoxic t lymphocyte epitope of a tumor-associated protein, survivin","volume":"8","author":"Hirohashi","year":"2002","journal-title":"Clin. Canc. Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352100255X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352100255X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:34:42Z","timestamp":1778542482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352100255X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":49,"alternative-id":["S030438352100255X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.05.031","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}